The Invisible Lag: Why MedTech Struggles with Inflation
When a company like GE Healthcare (NASDAQ: GEHC) sees its stock slide 11.3% in a single week, the market is usually reacting to a specific catalyst. In this case, the culprit isn’t a lack of demand—organic revenue guidance remains steady at 3%-4%—but rather a brutal collision between inflation and the “long sales cycle.”
For companies selling high-ticket imaging and visualization equipment, a sale isn’t a simple transaction. It is a multi-month, sometimes multi-year process involving hospital boards, government grants and complex procurement contracts. By the time a machine is delivered, the cost of the raw materials used to build it may have spiked, but the price is locked in by a contract signed a year prior.
This creates a margin squeeze that is challenging to escape quickly. While shorter-cycle products, such as pharmaceutical diagnostics and patient care equipment, provide some agility, they aren’t enough to offset the massive capital requirements of heavy imaging tech.
Tungsten, one of the raw materials currently driving up costs for GE Healthcare, is critical for medical imaging due to the fact that of its incredibly high melting point. It is used in X-ray tubes and CT scanners to withstand the intense heat generated during imaging processes.
The Tungsten and Chip Trap
The financial strain is not coming from a single source but a combination of systemic pressures. GE Healthcare management outlined $250 million in increased costs, split across three primary pain points:
- Memory Chips: $100 million in added costs, reflecting the ongoing volatility in the semiconductor market as AI integration increases demand for high-performance chips.
- Logistics: $100 million attributed to oil and freight costs, highlighting how sensitive global medical supply chains are to energy price swings.
- Raw Materials: $50 million driven by materials like tungsten.
These pressures resulted in a net reduction of $0.15 in earnings per share (EPS) for 2026, forcing a guidance drop to a range of $4.80 to $5, down from the previous $4.95 to $5.15.
Beyond the Dip: The Future of Healthcare Revenue Models
To avoid these inflationary traps in the future, the MedTech industry is likely to pivot toward more flexible financial models. The traditional “sell-and-service” model is being challenged by the rise of Everything-as-a-Service (XaaS).
The Rise of Equipment-as-a-Service (EaaS)
Rather than selling a multi-million dollar MRI machine in a one-time CapEx transaction, companies are exploring “Equipment-as-a-Service.” In this model, hospitals pay a monthly subscription or a per-scan fee. This shifts the financial burden from capital expenditure to operating expenditure (OpEx) for the hospital and provides the manufacturer with a recurring, predictable revenue stream.
More importantly, EaaS allows manufacturers to adjust pricing more dynamically. Instead of being locked into a price for three years, a subscription model allows for incremental adjustments that can better track with inflation.
When analyzing MedTech stocks during inflationary periods, look closely at the “backlog.” If a company has a massive backlog of orders signed at old prices, expect margin compression. The recovery begins when the “newly priced orders” start converting into revenue, as is expected for GE Healthcare heading into 2027.
AI as the Margin Savior
While memory chips are currently a cost burden, Artificial Intelligence is the long-term solution for margin recovery. AI is being integrated into imaging software to increase throughput—allowing hospitals to perform more scans per hour with the same equipment.
By shifting the value proposition from the hardware (which is subject to raw material inflation) to the software (which has near-zero marginal cost of distribution), companies can protect their profit margins. A software update that improves diagnostic accuracy can be priced as a premium service without requiring a single gram of tungsten or a shipment via freight.
Frequently Asked Questions
Why did GE Healthcare’s stock drop despite steady revenue?
The decline was driven by profit margin compression. While revenue is growing, the cost to produce and ship equipment has risen faster than the company can raise prices due to long-term sales contracts.
What is the “long sales cycle” in medical imaging?
It refers to the extended time between the initial pitch and the final delivery of high-cost equipment. Because these deals take months or years to close, companies cannot immediately pass inflation costs on to the customer.
Is this a long-term problem for MedTech companies?
Generally, no. As old contracts expire and new, higher-priced orders are fulfilled, margins typically recover. Analysts expect improvements for GE Healthcare later in 2026 and into 2027.
Join the Conversation
Do you think the shift toward “Equipment-as-a-Service” is the right move for hospitals, or does it create too much long-term dependency on manufacturers?
Share your thoughts in the comments below or subscribe to our newsletter for more deep dives into MedTech trends.
